BC
PTCT icon

Bridgefront Capital’s PTC Therapeutics PTCT Stock Holding History

Bridgefront Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,185
Closed -$242K – 719
2025
Q4 		$242K Buy
+3,185
New +$231K 0.06% 422
2025
Q2 		– Sell
-6,247
Closed -$318K – 805
2025
Q1 		$318K Buy
+6,247
New +$312K 0.09% 383
2021
Q2 		– Sell
-6,634
Closed -$314K – 843
2021
Q1 		$314K Buy
6,634
+687
+12% +$40.8K 0.1% 410
2020
Q4 		$363K Buy
+5,947
New +$351K 0.12% 304

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Bridgefront Capital's PTCT Position: Q1 2026 in Review

Bridgefront Capital sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 3,185 shares — an estimated $242K sold.

Bridgefront Capital first reported a position in PTCT in Q4 2020 and held it in 4 quarters. The position peaked at $363K in Q4 2020. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Bridgefront Capital reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bridgefront Capital sold 3,185 PTC Therapeutics shares in Q1 2026, an estimated $242K.
  • Bridgefront Capital first reported a position in PTC Therapeutics in Q4 2020 and held it in 4 quarters.
  • Bridgefront Capital's PTC Therapeutics position peaked at $363K in Q4 2020.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.